# Medtronic plc Moat

Status: published. Policy: company-analysis-1.

Medtronic demonstrates commercial demand, regulatory execution and cash generation, but the supplied passages do not establish a durable competitive advantage. Approved proprietary technologies are plausible differentiators; sustained superiority, customer switching costs and relative cost advantages remain unproven. Pricing power is constrained by procurement and reimbursement mechanisms, while realized price changes are undisclosed. This is insufficient evidence of a moat, rather than demonstrated absence of one.

## intangible_assets

Regulatory clearances and proprietary technologies provide current commercial capabilities and potential differentiation. Hugo's clearance and continued adoption of MiniMed systems are demonstrated milestones, but neither establishes a durable advantage over competing offerings.

Durability: Unestablished. Clinical testing and regulatory requirements impose development burdens, but the passages do not establish product exclusivity, patent coverage duration or persistent comparative superiority.

Risks: Patent expiry or circumvention, competing technologies, changing standards of care, quality failures and procurement pressure could erode differentiation. Historical industry market-share shifts show that positions can change; these disclosures do not establish Medtronic-specific share losses.

Invalidation: The differentiation thesis would weaken if approved platforms failed to sustain adoption, lost clearances, or suffered documented displacement following competing launches or adverse clinical findings. Establishing a moat would require evidence of persistent comparative clinical or commercial advantages, protected exclusivity, or customer switching friction.

Competitors: Not established
- [https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/mdt-20260424.htm](https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/mdt-20260424.htm) · 2026-06-18
- [https://www.sec.gov/Archives/edgar/data/1613103/000162828026060473/mdt-20260731.htm](https://www.sec.gov/Archives/edgar/data/1613103/000162828026060473/mdt-20260731.htm) · 2026-09-03
- [https://www.sec.gov/Archives/edgar/data/1613103/000161310326000010/mdt-20260816.htm](https://www.sec.gov/Archives/edgar/data/1613103/000161310326000010/mdt-20260816.htm) · 2026-08-17
- [https://www.sec.gov/Archives/edgar/data/1613103/000161310325000091/mdt-20250425.htm](https://www.sec.gov/Archives/edgar/data/1613103/000161310325000091/mdt-20250425.htm) · 2025-06-20
- [https://www.sec.gov/Archives/edgar/data/1613103/000161310324000072/mdt-20240426.htm](https://www.sec.gov/Archives/edgar/data/1613103/000161310324000072/mdt-20240426.htm) · 2024-06-20
- [https://www.sec.gov/Archives/edgar/data/1613103/000162828026011107/mdt-20260123.htm](https://www.sec.gov/Archives/edgar/data/1613103/000162828026011107/mdt-20260123.htm) · 2026-02-24

[JSON](https://beanvest.com/stock/mdt/moat.json)